Voyager Therapeutics Conference Call Summary Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Focus**: Development of gene therapies targeting neurodegenerative diseases, particularly Alzheimer's disease Key Industry Insights - **Year of Tau**: 2026 is referred to as the "year of tau" for Voyager, emphasizing the company's focus on tau-related therapies [2] - **Tau vs. A-beta**: The discussion highlights the ongoing debate regarding the role of tau and amyloid-beta (A-beta) in Alzheimer's disease, with evidence suggesting tau may be a more significant driver of cognitive decline [4][5][6] Core Developments 1. **Tau-targeted Assets**: - Two main assets targeting tau: an antibody and a gene therapy for tau knockdown [2] - Anticipated tau PET imaging data by the end of 2026 [2] - Gene therapy aims for a robust knockdown of tau in the brain, with expected reductions in the 50%-75% range across various cortical regions [12] 2. **Capsid Technology**: - Introduction of newly discovered blood-brain barrier (BBB)-penetrant capsids into clinical trials [2] - Two programs utilizing these capsids: one for tau knockdown and another partnered with Neurocrine for Friedreich's ataxia [3] - The goal is to demonstrate proof of concept for gene expression in the brain [3] 3. **Regulatory Engagement**: - Positive interactions with the FDA regarding the development of the tau knockdown gene therapy program [15][17] - Plans to use tau PET imaging to assess the reduction of pathological tau as a primary endpoint [17] Clinical Development and Strategy - **BIIB080 Data**: The upcoming data from BIIB080 is expected to be a significant catalyst for the gene therapy program, providing insights into the necessary tau reduction for clinical benefits [8][10] - **Antibody Development**: Voyager's antibody approach focuses on specific pathological forms of tau, with hopes of demonstrating efficacy in tau PET imaging and clinical outcomes [20][22][29] Market Considerations - **Timing of Intervention**: The company believes that interventions targeting tau may not need to occur as early as those targeting amyloid, suggesting a potential window for treatment even in mild to moderate dementia stages [30][34] - **Partnership Strategy**: Voyager is actively seeking partnerships to expand its reach and capabilities, leveraging collaborations with companies like Neurocrine, Novartis, and AstraZeneca [44][46] Additional Insights - **Novel Shuttle Technology**: Voyager is exploring the use of ALPL as a receptor for BBB penetration, which may offer advantages over traditional methods [37][39] - **Safety Considerations**: The potential safety risks associated with ALPL are acknowledged, particularly concerning severe loss of function leading to hypophosphatasia [43] Conclusion Voyager Therapeutics is positioned to make significant advancements in the treatment of neurodegenerative diseases, particularly through its focus on tau-targeted therapies and innovative delivery mechanisms. The upcoming data releases and regulatory interactions will be critical in shaping the company's future trajectory in the biotech landscape.

Financial Data and Key Metrics Changes - For Q1 2026, the company reported a net income of $30.8 million, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, approved for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [5][8] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. [20] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early results in weight loss and fat reduction [9][29] Market Data and Key Metrics Changes - The FDA approved Redemplo, marking a significant milestone for the company, with additional approvals from Health Canada and the Chinese National Medical Products Administration expected [8] - The company anticipates launching Redemplo in select EU countries and the U.K. later in 2026 [8] - The potential market for mixed hyperlipidemia, targeted by ARO-DimerPA, includes approximately 20 million people in the U.S. [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value offered to patients and healthcare systems [7] - Arrowhead aims to become cash flow positive and self-sustaining through multiple independent and partner launches, having completed transactions with gross proceeds of $1.33 billion [15][16] - The company is expanding its CNS portfolio with new delivery systems designed to penetrate the blood-brain barrier, targeting conditions like Alzheimer's disease [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to build on recent achievements and highlighted the potential for significant growth in 2026 and beyond [5][37] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran [37] - Management remains optimistic about the early feedback from payers and healthcare providers regarding Redemplo [21][57] Other Important Information - The company has strengthened its balance sheet significantly, with cash and investments totaling $917 million as of December 31, 2025 [34][35] - The company is not disclosing specific sales numbers for Redemplo until they become a meaningful driver of financials [32] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [41][42] Question: What are the timelines for discussions with the FDA regarding obesity treatments? - Discussions with the FDA are expected around mid-year, and an IND filing is anticipated shortly thereafter [44] Question: What level of reduction in LDL-C and triglycerides are you looking for with ARO-DimerPA? - A reduction of around 40%-50% in both LDL and triglycerides would be encouraging for advancing the asset [46][47] Question: How are you thinking about potential pricing for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [50][51] Question: Can you discuss the pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [53][54] Question: Has the pricing for Redemplo been discussed in relation to the SHTG market? - The focus is on ensuring coverage and access for high-risk patients, with discussions reflecting the clinical and economic value of Redemplo [56][59]